Unassociated Document


    

      

    

    Press
      Release

    Source:
      Senetek PLC

    


    


    


    SENETEK
      ANNOUNCES MARKETING COLLABORATION FOR NEW GENERATION CYTOKININ WITH TRIAX
      AESTHETICS LLC

    


    Senetek
      Guaranteed $10.8 Million Minimum in First Year

    Product
      to be Packaged Under a Senetek PLC/Triax Label 

    Senetek
      to Contribute $4.5 Million to First Year Sales and Marketing Budget


    


    


    NAPA,
      California, August 6, 2007 - Senetek PLC (OTCNBB:SNTKY), www.senetekplc.com
      , a
      specialty dermatology and skin care company targeting the science of aging,
      today announced a Marketing Collaboration Agreement for its second-generation
      cytokinin with Triax Aesthetics LLC, a Cranford, New Jersey based company
      focused on quality of life for patients with dermatologic
      conditions.

    


    Under
      the
      terms of the Agreement, Senetek has granted Triax an exclusive license in the
      ethical market channel in the United States and its territories, Canada and
      select Middle East countries. All product packaging will be labeled
      Senetek/Triax. 

    


    Senetek
      will be responsible for production and supply of products, will contribute
      periodic sales and marketing payments totaling $4.5 million in the first year
      of
      the Agreement and will participate in the product marketing strategy. In return,
      Senetek will receive all net product revenues in the first year of the
      Agreement, with a guaranteed minimum of $10.8 million in 2008. The Agreement
      calls for increased minimum sales annually after the first year. Subsequent
      to
      the first year of the Agreement, the companies will share net revenues on a
      50/50 basis. Triax will be responsible for all sales, marketing and order
      fulfillment during the life of the Agreement.

    


    Triax
      Aesthetics is a specialty dermatology company managed by Joseph J. Krivulka
      and
      Leonard L. Mazur. Mr. Krivulka and Mr. Mazur have extensive experience in
      specialty dermatology including high level positions at Lederle Laboratories,
      Sandoz Pharmaceuticals, Mylan Laboratories, Cooper Laboratories, ICN
      Pharmaceuticals and Knoll Pharmaceutical Company. In addition, Mr. Krivulka
      was
      a founder of Bertek Pharmaceuticals and co-founder of Reliant Pharmaceuticals
      and Triax Pharmaceuticals LLC. Mr. Mazur was a founding executive of Medicis
      Pharmaceuticals and founder of Genesis Pharmaceutical.

    


    


    Frank
      J.
      Massino, Chairman and Chief Executive Officer of Senetek PLC, stated “we are
      most pleased with forming a marketing collaboration with Triax and its
      highly respected management team. In addition, by having the Senetek name on
      the
      packaging, the Company will be afforded greater visibility in both the
      dermatological and financial markets.  This transaction is the beginning of
      a new and superior business model which will increase revenues and create brand
      recognition for Senetek”.

    


    Joseph
      J.
      Krivulka and Leonard L. Mazur of Triax Aesthetics LLC, commented, “we are
      extremely pleased to join forces with Senetek, a pioneer in research and product
      development in the worldwide anti aging market. Our objective is to be the
      market leader in the double-digit annual growth anti aging skin care market
      and
      to achieve more than $100 million in annual sales”. 

    

      831A
        LATOUR COURT • NAPA, CALIF 94558 • 707.226.3900 

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      



    About
      Senetek PLC

    


    Senetek
      PLC (OTCBB: SNTKY) is a specialty dermatology and skincare company with a
      portfolio of intellectual properties targeting the science of aging, including
      skincare and dermatological therapeutics, erectile dysfunction and nutrition.
      Senetek recently granted Valeant Pharmaceuticals a paid up license for Senetek's
      first generation patented skin care active ingredient Kinetin and its analog
      Zeatin in return for $21 million cash and forgiveness of $6 million prepaid
      royalty credit, and is negotiating third party license agreements for new
      patent-pending second generation dermatological active ingredients and is
      completing development of a number of additional compounds. In addition, Senetek
      has entered into exclusive licenses for Europe and North America, respectively,
      for Invicorp®, has an exclusive manufacturing distributorship for its
      proprietary diagnostic monoclonal antibodies, and recently sold, with retained
      rights of profit participation, its patented drug delivery system, Reliaject®.


    


    For
      more
      information, visit the company's website at  http://www.senetekplc.com.

    


    


    This
      news release contains statements that may be considered 'forward-looking
      statements' within the meaning of the Private Securities Litigation Reform
      Act,
      including those that might imply FDA approval and commercial potential for
      Invicorp. Forward-looking statements by their nature involve substantial
      uncertainty, and actual results may differ materially from those that might
      be
      suggested by such statements. Important factors identified by the Company that
      it believes could result in such material differences are described in the
      Company's Annual Report on Form 10-K/A for the year 2006. However, the Company
      necessarily can give no assurance that it has identified or will identify all
      of
      the factors that may result in any particular forward-looking statement
      materially differing from actual results, and the Company assumes no obligation
      to correct or update any forward-looking statements which may prove to be
      inaccurate, whether as a result of new information, future events or
      otherwise.

    


    Company
      contact:

    William
      F. O’Kelly

    Chief
      Financial Officer

    Senetek,
      PLC

    1-707-226-3900
      ext. 102

    
831A
      LATOUR COURT • NAPA,
      CALIF 94558 • 707.226.3900